A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Brigatinib (Alunbrig)

Brigatinib targets specific kinase enzymes involved in cancer cell growth and proliferation.

First FDA approval2017-04-28
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$71.0M in CY2024 Part D spend4K claims · 640 beneficiaries · 329 plans surveyed

Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
1308 / 329
Substantial PA friction across plans.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Brigatinib used for?

Brigatinib targets specific kinase enzymes involved in cancer cell growth and proliferation.

Is there a generic for Brigatinib?

No. Brigatinib is brand-only with no generic equivalents currently in market.

How much does my plan pay for Brigatinib?

NADAC pricing data not currently available for this drug.

Is Brigatinib on the FDA shortage list?

No. Brigatinib is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Kinase Inhibitor6 alternatives in D1
01
Everolimus
Brand: Afinitor
$2.29Lowest NADAC
10Generic mfrs
$259.1MCY24 Part D spend
Compare →
02
Imatinib
Brand: Gleevec
$0.827Lowest NADAC
12Generic mfrs
$318.0MCY24 Part D spend
Compare →
03
Dasatinib
Brand: PHYRAGO
$29.19Lowest NADAC
8Generic mfrs
$850.6MCY24 Part D spend
Compare →
04
Everolimus Tablets
Brand: Everolimus
$2.29Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
05
Ruxolitinib
Brand: JAKAFI
$34.14Lowest NADAC
0Generic mfrs
$3.38BCY24 Part D spend
Compare →
06
Sunitinib Malate
Brand: SUTENT
Lowest NADAC
8Generic mfrs
$69.0MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (3 approvals on file) · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.